Senate Unlikely To Consider Rx Import Legislation This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate is unlikely to consider drug importation legislation this year
You may also be interested in...
Rx Reimport Ban Should Be Lifted, Supply Controls Allowed, Cato Institute Says
Drug manufacturers should be free to pursue market segmentation through their global pricing decisions, a report by the Cato Institute states. The think tank endorsed Rx import legislation, while advocating the use of contractual mechanisms to segment markets.
Rx Reimport Ban Should Be Lifted, Supply Controls Allowed, Cato Institute Says
Drug manufacturers should be free to pursue market segmentation through their global pricing decisions, a report by the Cato Institute states. The think tank endorsed Rx import legislation, while advocating the use of contractual mechanisms to segment markets.
President Bush Signs Australia Free Trade Act
The U.S. pharmaceutical industry has its first formal mechanism to challenge foreign price controls following the signing of the U.S.-Australia free trade agreement by President Bush Aug. 3